A new little shell company called Immunis ( IMMC) has recently bought the 25% of the worldwide rights to a Diabetes II drug called Diab II. The drug is airly new and has not yet been marketed. The company has bypassed the FDA and sought richer pastures in the international marketplace. Slaes in China and Hong Kong have been excellent and there is a strong push to expose the drug to the Caribean and South America.
A medical fund in Toronto I spoke with has taken a considerable interest in the company and is presently negotiating for Canadian rights and possibly (African/Middle Eastern). This is a $200 billion marketplace and the company thinks it can capture 1% by year end.
The share structure is excellent 7.5m shares 6.8million restricted held by one company a holding company. IMMC itself is a holding company and hence has no costs or associated expenses on 25% of the revenues...the shares are currently trading at 3.30 and have little opposition through $5 where they will take the stock to National board.
I like the deal on a short twerm jump to $5 and a long term hold much higher.
comments?
Monte |
